The promise of open innovation in drug discovery: An industry perspective

Future Medicinal Chemistry

Volumn 7, Issue 14, 2015, Pages 1835-1838

  Rees, Steve ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

High throughput screening; lead discovery; open innovation

Indexed keywords

BIOTECHNOLOGY; CHRONIC DISEASE; CLINICAL RESEARCH; CLINICAL STUDY; DRUG DEVELOPMENT; DRUG INDUSTRY; EDITORIAL; EUROPE; FUNDING; HIGH THROUGHPUT SCREENING; HUMAN; MEDICAL SOCIETY; MOLECULAR LIBRARY; MOLECULE; PRIORITY JOURNAL; PRODUCTIVITY; SCIENTIST; SOCIAL WELFARE; UNITED STATES; ECONOMICS; INVENTION;

DRUG DISCOVERY; DRUG INDUSTRY; HIGH-THROUGHPUT SCREENING ASSAYS; INVENTIONS;

EID: 84945263165     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.125     Document Type: Editorial

References (15)

1. Frye S. US academic drug discovery. Nat. Rev. Drug Disc. 10, 409-410 (2011
2. Austin CP, Brady LS, Insel TR, Collins FS. NIH molecular libraries initiative. Science 306, 1138-1139 (2004
3. Mullarrd A. European Lead Factory opens for business. Nat. Rev. Drug Disc. 12, 173-175 (2013
4. Shanks E, Ketteler R, Ebner D. Academic drug discovery within the United Kingdom: a reassessment. Nat. Rev. Drug Disc. 14, 510 (2015
5. Frank R. EU-OPENSCREEN - A european infrastructure of open screening platforms for chemical biology. ACS Chem. Biol. 9, 853-854 (2014
6. Chung TDY. Collaborative pre-competitive preclinical drug discovery with academics and pharma/biotech partners at Sanford/Burnham: infrastructure, capabilities and operational models. Comb. Chem. High Throughput Scr. 17, 272-289 (2014
7. Hudson J, Khazzragui HF. Into the valley of death: research to innovation. Drug Disc. Today 18, 610-614 (2013
8. Chesbrough HW. MIT Sloan Management Review 44, 35-41 (2003
9. Schumacher A, Germann PG, Gassmann O. Models for OI in the pharmaceutical industry. Drug Disc. Today 18, 1133-1137 (2013
10. Paul SM, Mytelka DS, Dunwidde CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Disc. 9, 203-214 (2010
11. Cook D, Brown D, Alexander R, et al. Lessons learnt from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat. Rev. Drug Disc. 13, 419-531 (2014
12. Simpson PB, Reichman M. Opening the lead generation toolbox. Nat. Rev. Drug Disc. 13, 3-4 (2014
13. Cumming J, Davis AM, Muresan S, Haeberlein M, Chen H. Chemical predictive modeling to improve compound quality. Nat. Rev. Drug Disc. 12, 948-962 (2013
14. Kojel T, Blomberg N, Greasley PJ, et al. Big pharma screening collections: more of the same or unique libraries: the AstraZeneca-Baher Pharma AG case. Drug Disc. Today 18, 1014-1024 (2012
15. Gileadi O, Knapp S, Lee WH, et al. The scientific impact of the Structural Genomic Cnsortium: a protein family and ligand-centred approach to medically-relevant human proteins. J. Struct. Funct. Genomics 8, 107-119 (2007